Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureS Alice Long, Cate Speake
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
10.1016/s2213-8587(26)00191-9 · 2026
Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I/II randomised, double-blind, placebo-controlled, dose-finding study
10.1007/s00125-020-05200-w · 2020
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
10.1172/jci.insight.99306 · 2018
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes
10.1126/scitranslmed.adn2404 · 2024
Durable control of autoimmunity requires sustained stimulation of regulatory T cells
10.1016/j.celrep.2026.117292 · 2026
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function
10.2337/db12-0049 · 2012
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
10.1172/jci.insight.147474 · 2021
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study
10.1016/s0140-6736(26)01143-8 · 2026
No additional external references are available.